E-Cigarette Liquids and Aldehyde Flavoring Agents Inhibit CYP2A6 Activity in Lung Epithelial Cells

被引：3
作者：
Winters, Brett R. [1 ,2 ]
Clapp, Phillip W. [1 ,3 ]
Simmons, Steven O. [4 ]
Kochar, Tavleen K. [5 ]
Jaspers, Ilona [1 ,3 ]
Madden, Michael C. [6 ,7 ]
机构：
[1] Univ North Carolina Chapel Hill, Curriculum Toxicol & Environm Med, Chapel Hill, NC 27514 USA
[2] Cytokinetics Inc, South San Francisco, CA 94080 USA
[3] Univ North Carolina Chapel Hill, Ctr Environm Med Asthma & Lung Biol, Chapel Hill, NC 27514 USA
[4] US EPA, Ctr Computat Toxicol & Exposure, ORD, Chapel Hill, NC 27711 USA
[5] Univ North Carolina Chapel Hill, Dept Chem, Chapel Hill, NC 27514 USA
[6] US EPA, Formerly Publ Hlth & Integrat Toxicol Div, ORD, Chapel Hill, NC 27517 USA
[7] US EPA, Formerly Publ Hlth & Integrat Toxicol Div, ORD, 12 Oakwood Dr, Chapel Hill, NC 27517 USA
来源：
ACS OMEGA | 2023年 / 8卷 / 12期
基金：
美国国家卫生研究院;
关键词：
IN-VITRO; METABOLISM; NICOTINE; PROTEINS; ASSAYS;
D O I：
10.1021/acsomega.2c08258
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
Certain e-liquids and aromatic aldehyde flavoring agents were previously identified as inhibitors of microsomal recombinant CYP2A6, the primary nicotine-metabolizing enzyme. However, due to their reactive nature, aldehydes may react with cellular components before reaching CYP2A6 in the endoplasmic reticulum. To determine whether e-liquid flavoring agents inhibited CYP2A6 in a cellular system, we investigated their effects on CYP2A6 using BEAS-2B cells transduced to overexpress CYP2A6. We demonstrated that two e-liquids and three aldehyde flavoring agents (cinnamaldehyde, benzaldehyde, and ethyl vanillin) exhibited dose-dependent inhibition of cellular CYP2A6.
引用
收藏
页码：11261 / 11266
页数：6
相关论文
共 21 条
  • [1] Mentholated cigarette smoking inhibits nicotine metabolism
    Benowitz, NL
    Herrera, B
    Jacob, P
    [J]. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2004, 310 (03) : 1208 - 1215
  • [2] The conduct of in vitro and in vivo drug-drug interaction studies: A Pharmaceutical Research and Manufacturers of America (PhRMA) perspective
    Bjornsson, TD
    Callaghan, JT
    Einolf, HJ
    Fischer, V
    Gan, L
    Grimm, S
    Kao, J
    King, SP
    Miwa, G
    Ni, L
    Kumar, G
    McLeod, J
    Obach, RS
    Roberts, S
    Roe, A
    Shah, A
    Snikeris, F
    Sullivan, JT
    Tweedie, D
    Vega, JM
    Walsh, J
    Wrighton, SA
    [J]. DRUG METABOLISM AND DISPOSITION, 2003, 31 (07) : 815 - 832
  • [3] Flavored e-cigarette liquids and cinnamaldehyde impair respiratory innate immune cell function
    Clapp, Phillip W.
    Pawlak, Erica A.
    Lackey, Justin T.
    Keating, James E.
    Reeber, Steven L.
    Glish, Gary L.
    Jaspers, Ilona
    [J]. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY, 2017, 313 (02) : L278 - L292
  • [4] Global Analysis of Protein Damage by the Lipid Electrophile 4-Hydroxy-2-nonenal
    Codreanu, Simona G.
    Zhang, Bing
    Sobecki, Scott M.
    Billheimer, Dean D.
    Liebler, Daniel C.
    [J]. MOLECULAR & CELLULAR PROTEOMICS, 2009, 8 (04) : 670 - 680
  • [5] The endoplasmic reticulum in xenobiotic toxicity
    Cribb, AE
    Peyrou, M
    Muruganandan, S
    Schneider, L
    [J]. DRUG METABOLISM REVIEWS, 2005, 37 (03) : 405 - 442
  • [6] Fluorescence-based assays for screening nine cytochrome P450 (P450) activities in intact cells expressing individual human P450 enzymes
    Donato, MT
    Jiménez, N
    Castell, JV
    Gómez-Lechón, MJ
    [J]. DRUG METABOLISM AND DISPOSITION, 2004, 32 (07) : 699 - 706
  • [7] An overview of the chemistry and biology of reactive aldehydes
    Fritz, Kristofer S.
    Petersen, Dennis. R.
    [J]. FREE RADICAL BIOLOGY AND MEDICINE, 2013, 59 : 85 - 91
  • [8] A high throughput screening assay to screen for CYP2E1 metabolism and inhibition using a fluorogenic Vivid® P450 substrate
    Marks, BD
    Smith, RW
    Braun, HA
    Goossens, TA
    Christenson, M
    Ozers, MS
    Lebakken, CS
    Trubetskoy, OV
    [J]. ASSAY AND DRUG DEVELOPMENT TECHNOLOGIES, 2002, 1 (01) : 73 - 81
  • [9] Messina ES, 1997, J PHARMACOL EXP THER, V282, P1608
  • [10] Neve EPA, 2010, CURR OPIN DRUG DISC, V13, P78
123